Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.

Gaurav NarulaNirmalaya D PradhanBrijesh AroraSripad D Banavali

Published in: Pediatric blood & cancer (2018)

RO+LCH receiving oral etoposide augmented induction and maintenance had early and durable responses. Prolonging maintenance lowered reactivation rates in RO+ and RO-LCH, resulting in excellent survival.

Keyphrases

papillary thyroid
single cell
randomized controlled trial
squamous cell carcinoma
mesenchymal stem cells
lymph node metastasis
bone marrow